Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients

P. Bradáčová, L. Slavík, J. Úlehlová, E. Kriegová, E. Jará, L. Bultasová, D. Friedecký, J. Ullrychová, J. Procházková, A. Hluší, G. Manukyan, L. Štefaničková

. 2023 ; 11 (12) : . [pub] 20231216

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23022302

The aim of this study was to determine the thrombogenicity of lupus anticoagulant (LA) antibodies using a modified thrombin generation assay (TGA) with the addition of activated protein C (APC) in a group of 85 patients with LA-positive samples. Of these, 58 patients had clinical manifestations of antiphospholipid syndrome (APS) according to the Sydney criteria classification, i.e., each patient had thrombosis or foetal loss, and 27 patients did not show any clinical manifestations of APS. A comparison of the two groups' TGA results revealed statistically significant differences (Fisher's test p = 0.0016). The group of patients exhibiting clinical manifestations of APS showed higher thrombogenicity in 56.9% of patients, while the group of patients not yet exhibiting clinical manifestations of APS showed higher thrombogenicity in 25.9% of patients. There were no significant differences in the specificity of the TGA test between the groups of patients exhibiting similar clinical manifestations. Receiver operating characteristic curve analysis showed a more significant relationship (p = 0.0060) for TGA than for LA titre (p = 0.3387). These data suggest that the determination of LA thrombogenicity with the TGA assay leads to an increased prediction of the manifestation of a thromboembolic event. Our findings appear to be particularly relevant for the prediction of thrombotic events in patients with laboratory-expressed APS and no clinical manifestations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022302
003      
CZ-PrNML
005      
20240116163010.0
007      
ta
008      
240105s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines11123329 $2 doi
035    __
$a (PubMed)38137550
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bradáčová, Pavla $u Department Clinical Hematology, Masaryk Hospital Ústí nad Labem, 40113 Ústi nad Labem, Czech Republic $u Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic $1 https://orcid.org/0000000318864432
245    10
$a Determining Thrombogenicity: Using a Modified Thrombin Generation Assay to Detect the Level of Thrombotic Event Risk in Lupus Anticoagulant-Positive Patients / $c P. Bradáčová, L. Slavík, J. Úlehlová, E. Kriegová, E. Jará, L. Bultasová, D. Friedecký, J. Ullrychová, J. Procházková, A. Hluší, G. Manukyan, L. Štefaničková
520    9_
$a The aim of this study was to determine the thrombogenicity of lupus anticoagulant (LA) antibodies using a modified thrombin generation assay (TGA) with the addition of activated protein C (APC) in a group of 85 patients with LA-positive samples. Of these, 58 patients had clinical manifestations of antiphospholipid syndrome (APS) according to the Sydney criteria classification, i.e., each patient had thrombosis or foetal loss, and 27 patients did not show any clinical manifestations of APS. A comparison of the two groups' TGA results revealed statistically significant differences (Fisher's test p = 0.0016). The group of patients exhibiting clinical manifestations of APS showed higher thrombogenicity in 56.9% of patients, while the group of patients not yet exhibiting clinical manifestations of APS showed higher thrombogenicity in 25.9% of patients. There were no significant differences in the specificity of the TGA test between the groups of patients exhibiting similar clinical manifestations. Receiver operating characteristic curve analysis showed a more significant relationship (p = 0.0060) for TGA than for LA titre (p = 0.3387). These data suggest that the determination of LA thrombogenicity with the TGA assay leads to an increased prediction of the manifestation of a thromboembolic event. Our findings appear to be particularly relevant for the prediction of thrombotic events in patients with laboratory-expressed APS and no clinical manifestations.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Slavík, Luděk $u Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Úlehlová, Jana $u Department of Hemato-Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Kriegová, Eva $u Department of Immunology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Jará, Eliška $u Department Clinical Hematology, Masaryk Hospital Ústí nad Labem, 40113 Ústi nad Labem, Czech Republic
700    1_
$a Bultasová, Lenka $u Department Hematology and Biochemistry, University Hospital, 32300 Plzeň, Czech Republic
700    1_
$a Friedecký, David $u Laboratory for Inherited Metabolic Disorders, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic $1 https://orcid.org/0000000234489073 $7 xx0142900
700    1_
$a Ullrychová, Jana $u Department Clinical Hematology, Masaryk Hospital Ústí nad Labem, 40113 Ústi nad Labem, Czech Republic
700    1_
$a Procházková, Jana $u Department of Hemato-Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Hluší, Antonín $u Department of Hemato-Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Manukyan, Gayane $u Department of Immunology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic $u Laboratory of Molecular and Cellular Immunology, Institute of Molecular Biology NAS RA, Yerevan 0014, Armenia
700    1_
$a Štefaničková, Lenka $u Laboratory for Inherited Metabolic Disorders, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 11, č. 12 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38137550 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240116163007 $b ABA008
999    __
$a ok $b bmc $g 2036234 $s 1208747
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 11 $c 12 $e 20231216 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
LZP    __
$a Pubmed-20240105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace